Rodriguez-Remirez M, et al. - Because neuroendocrine carcinoma (NEC) is a rare and highly aggressive tumor, researchers in vivo assessed whether anti-VEGF drugs could be a therapeutic alternative for those tumors with poor prognosis. Two xenograft models have been developed using either lung (H460) or colon (COLO320)-derived human cell line NEC to assess the effect of two antiangiogenic drugs, aflibercept and bevacizumab, on tumor growth and their pathological features. In addition, tumors have been subjected to staining by immunohistochemistry and proteins have been measured with western blot and ELISA. There was significant antitumor activity in both aflibercept and bevacizumab. Aflibercept resulted in tumor growth inhibition (TGI) of 94% in the H460 model, and bevacizumab treatment resulted in TGI of 72.2%. Likewise, aflibercept and bevacizumab resulted in 89.3% and 84% TGI respectively in the COLO320 model. This investigation strongly supports anti-VEGF therapies as a novel therapeutic option in NECs, particularly aflibercept.